HSP90AB1 and psoriasis: In fact, preclinical or clinical studies revealed that using Hsp90 inhibitors with N-terminal affinity seems to be promising for the treatment of non-infectious inflammatory skin diseases (Ben Abdallah et al. 2023) including autoimmune bullous skin diseases or psoriasis due to attenuation of numerous inflammatory immune cells and signaling pathways (Kasperkiewicz et al. 2011; Tukaj et al. 2013, 2014a, 2017; Li et al. 2020; Bregnhøj et al. 2022; Rittig et al. 2023).